6 results match your criteria: "The Netherlands m.drent@maastrichtuniversity.nl.[Affiliation]"
Lung
October 2015
ild care foundation research team, PO Box 18, 6720 AA, Bennekom, The Netherlands.
Background: Sarcoidosis patients suffer from fatigue and exercise limitation. The aim of this study was to establish whether a physical training program improves these and other outcomes important to sarcoidosis patients.
Methods: From 11/2012 to 9/2014, 201 sarcoidosis patients were referred to the ild care expertise team, Ede, the Netherlands.
Eur Respir J
June 2014
Dept of Interstitial Lung Diseases, Gelderse Vallei Hospital, Ede, The Netherlands Dept of Toxicology, Maastricht University, Maastricht, The Netherlands
Responsiveness to tumour necrosis factor (TNF) inhibitors has been associated with the TNF-α G-308A polymorphism in rheumatoid arthritis. The aim of this study was to examine the association between the presence of this polymorphism and the response to TNF inhibitors in patients with refractory sarcoidosis. Patients (n=111) who started TNF-inhibitor treatment (76 infliximab, 35 adalimumab) were followed for at least 1 year.
View Article and Find Full Text PDFEur Respir J
November 2012
University Maastricht, FHML, Maastricht, 6202 NC, The Netherlands.
Curr Opin Pulm Med
January 2013
Department of Interstitial Lung Diseases, Hospital Gelderse Vallei, Ede, The Netherlands.
Curr Med Chem
May 2013
Faculty of Health, Medicine and Life Science, University Maastricht, Faculty of Health, Medicine and Life Science, UNS 40 room 4.550, PO Box 3100 6202 NC Maastricht, The Netherlands.
Medicinal agents, beside occupational and environmental agents, remain one of the most common causes for interstitial lung diseases (ILD). A major problem with ILD is the recognition of the causative agent. In some cases more or less characteristic features of presentation are described.
View Article and Find Full Text PDFEur Respir J
July 2012
Dept of Interstitial Lung Diseases, Hospital Gelderse Vallei, Ede, The Netherlands.
Sarcoidosis-associated fatigue is globally recognised as a disabling symptom. Fatigue has been reported in up to 50-70% of sarcoidosis patients, causing impaired quality of life. The aetiology of this troublesome problem remains elusive and is usually multifactorial.
View Article and Find Full Text PDF